BACKGROUND: Heart failure is an inflammatory disease. Patients with acute decompensated heart failure (ADHF) exhibit significant inflammatory activity on admission. We hypothesized that Interleukin-1 blockade, with anakinra (Kineret, Swedish Orphan Biovitrum), would quench the acute inflammatory response in patients with ADHF. METHODS: We randomized 30 patients with ADHF, reduced left ventricular ejection fraction (<40%), and elevated C reactive protein (CRP) levels (≥5 mg/L) to eitheranakinra 100 mg twice daily for 3 days followed by once daily for 11 days or matching placebo, in a 1:1 double blinded fashion. We measured daily CRP plasma levels using a high-sensitivity assay during hospitalization and then again at 14 days and evaluated the area-under-the-curve and interval changes (delta). RESULTS: Treatment with anakinra was well tolerated. At 72 hours, anakinra reduced CRP by 61% versus baseline, compared with a 6% reduction among patients receiving placebo (P = 0.004 anakinra vs. placebo). CONCLUSIONS:Interleukin-1 blockade with anakinra reduces the systemic inflammatory response in patients with ADHF. Further studies are warranted to determine whether this anti-inflammatory effect translates into improved clinical outcomes.
RCT Entities:
BACKGROUND:Heart failure is an inflammatory disease. Patients with acute decompensated heart failure (ADHF) exhibit significant inflammatory activity on admission. We hypothesized that Interleukin-1 blockade, with anakinra (Kineret, Swedish Orphan Biovitrum), would quench the acute inflammatory response in patients with ADHF. METHODS: We randomized 30 patients with ADHF, reduced left ventricular ejection fraction (<40%), and elevated C reactive protein (CRP) levels (≥5 mg/L) to either anakinra 100 mg twice daily for 3 days followed by once daily for 11 days or matching placebo, in a 1:1 double blinded fashion. We measured daily CRP plasma levels using a high-sensitivity assay during hospitalization and then again at 14 days and evaluated the area-under-the-curve and interval changes (delta). RESULTS: Treatment with anakinra was well tolerated. At 72 hours, anakinra reduced CRP by 61% versus baseline, compared with a 6% reduction among patients receiving placebo (P = 0.004 anakinra vs. placebo). CONCLUSIONS:Interleukin-1 blockade with anakinra reduces the systemic inflammatory response in patients with ADHF. Further studies are warranted to determine whether this anti-inflammatory effect translates into improved clinical outcomes.
Authors: C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: Luc W Eurlings; Sandra Sanders-van Wijk; Roland van Kimmenade; Aart Osinski; Lidwien van Helmond; Maud Vallinga; Harry J Crijns; Marja P van Dieijen-Visser; Hans-Peter Brunner-La Rocca; Yigal M Pinto Journal: J Am Coll Cardiol Date: 2012-09-26 Impact factor: 24.094
Authors: Sheryl L Chow; Stephen A O'Barr; Jessica Peng; Eric Chew; Firooz Pak; Ryan Quist; Paryus Patel; J Herbert Patterson; J Thomas Heywood Journal: J Card Fail Date: 2010-12-03 Impact factor: 5.712
Authors: Patrícia Lourenço; José Paulo Araújo; Cristiana Paulo; Joana Mascarenhas; Fernando Friões; Ana Azevedo; Paulo Bettencourt Journal: Clin Cardiol Date: 2010-11 Impact factor: 2.882
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino Journal: Circulation Date: 2003-03-25 Impact factor: 29.690
Authors: Leo F Buckley; Salvatore Carbone; Cory R Trankle; Justin M Canada; Claudia Oddi Erdle; Jessica A Regan; Michele M Viscusi; Dinesh Kadariya; Hayley Billingsley; Ross Arena; Antonio Abbate; Benjamin W Van Tassell Journal: J Cardiovasc Pharmacol Date: 2018-07 Impact factor: 3.105
Authors: Cory R Trankle; Justin M Canada; Dinesh Kadariya; Roshanak Markley; Horacio Medina De Chazal; Janet Pinson; Adam Fox; Benjamin W Van Tassell; Antonio Abbate; Daniel Grinnan Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405
Authors: Benjamin W Van Tassell; Justin Canada; Salvatore Carbone; Cory Trankle; Leo Buckley; Claudia Oddi Erdle; Nayef A Abouzaki; Dave Dixon; Dinesh Kadariya; Sanah Christopher; Aaron Schatz; Jessica Regan; Michele Viscusi; Marco Del Buono; Ryan Melchior; Pranav Mankad; Juan Lu; Robin Sculthorpe; Giuseppe Biondi-Zoccai; Edward Lesnefsky; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2017-11 Impact factor: 8.790
Authors: Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790